Advanced Lung Cancer

An investigational viral immunotherapy extended survival compared with standard care for patients with advanced non-small cell lung cancer who had inadequate response to immune checkpoint inhibitor therapy, phase 2 trial results showed.

The first-line combination of amivantamab-vmjw plus lazertinib extended OS compared with osimertinib for patients with EGFR-mutated advanced non-small cell lung cancer, according to data from the randomized phase 3 MARIPOSA trial.

A two-drug combination extended OS compared with standard first-line osimertinib for certain patients with advanced lung cancer, according to the agents’ manufacturer.

Treatment with immune checkpoint inhibitors appeared linked with higher risk for venous thromboembolism among adults with metastatic lung cancer, according to study results presented at CHEST Annual Meeting.

A randomized phase 3 trial designed to evaluate tiragolumab plus atezolizumab for certain patients with advanced lung cancer failed to meet its co-primary endpoint of OS, according to the agents’ manufacturer

Data from a phase 3 trial designed to compare pralsetinib with standard therapy for certain patients with advanced lung cancer revealed a risk for severe — and potentially fatal — infections with the drug, according to its manufacturer.

In this edition, FDA approves Rybrevant for advanced lung cancer, screening orders in eligible patients higher with digital health program and more.

The FDA approved tumor treating fields for use as part of combination treatment for certain patients with metastatic non-small cell lung cancer.

The introduction of immunotherapy to treatment paradigms has improved survival for patients with metastatic non-small cell lung cancer, according to study results.

CHICAGO — A stepped palliative care model delivering early care at key points for patients with advanced cancer resulted in fewer visits while still maintaining quality-of-life benefits, results from a randomized study showed.